Jingjing Zhang

National University of Singapore (NUS)

Singapore

Research Interests

Explore related searches

Professors in Medical Imaging

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Frankis Almaguel

Loma Linda University Medical Center

UNITED STATES

View details

Xiaoyuan Chen

Chaired Professor

National University of Singapore (NUS)

SINGAPORE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jingjing Zhang

Research Interests

Explore related searches

Contact this professor

Articles (16)

Targeted Radionuclide Therapy in Glioblastoma

Engineered Antibodies as Cancer Radiotheranostics

Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles

Exploiting Albumin as a Versatile Carrier for Cancer Theranostics

Clinical translation of radiotheranostics for precision oncology

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”

Prostate-specific membrane antigen radioligand therapy using <sup>177</sup>Lu-PSMA I&T and <sup>177</sup>Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.

225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation.

Somatostatin receptor imaging with [<sup>68</sup>Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma.

Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using <sup>177</sup>Lu-FAP-2286: First-in-Human Results.

First-in-Humans Study of the SSTR Antagonist <sup>177</sup>Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.

Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery.

Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of <sup>177</sup>Lu-DOTA-EB-TATE.

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).

177Lu-DOTATOC Peptide Receptor Radionuclide Therapy in a Patient With Neuroendocrine Breast Carcinoma and Breast Invasive Ductal Carcinoma.

Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide Therapy.

Collaborators (2)

Frankis Almaguel

Xiaoyuan Chen

Make your next move.